Rybodyn
2 known investors
Find your way into Rybodyn
153 people in our graph share verified history with the Rybodyn team — schools, employers, funds. One of them is your warm intro.
Rishi Modiunlockedknows Ashley Woodfin · together at Northwestern University - The Feinberg School of Medicine (overlapped)
×2knows the team · via Scale Biosciences
knows the team · via Syntheticgenomics
×3knows the team · via Michigan State University
×4knows the team · via University of California, San Diego - Rady School of Management
knows the team · via Scripps Research
RyboDyn develops breakthrough immunotherapies by identifying and targeting previously hidden disease markers through its proprietary RyboCypher™ technology platform. The company serves patients in need of next-generation treatments for diseases associated with cryptic biological targets.
Founders & leadership
IA
Imad AjjawiinCo-Founder & Chief Executive OfficerImad Ajjawi founded Denovium, an AI-driven protein discovery and design company, which was subsequently acquired by Absci. He is the co-founder and CEO of RyboDyn, which develops immunotherapies using its proprietary RyboCypher™ technology platform.
CD
Corey DambacherinFounder, President, & Chief Technology OfficerDr. Corey Dambacher holds a Ph.D. in chemistry from Scripps Research and has worked on synthetic biology and platform development, including at Omniome prior to its 2021 acquisition. He is the Founder, President, and Chief Technology Officer of RyboDyn, a biotechnology company developing immunotherapies targeting the dark proteome.
KW
Kerry WilsoninCo-Founder & VP, Platform Development
AW
Ashley WoodfininCo-Founder & Bioinformatics Lead - Target DiscoveryWith over a decade of experience in computational analysis for sequencing platforms, she has worked on dark RNA sequencing, proteogenomic target discovery, single-cell and epigenomic methods, and functional genomics across immunotherapy and early detection applications, including roles at Scale Biosciences (acquired by 10x Genomics).
Investors · 2
In the news
Frequently asked questions
- What does Rybodyn do?
- RyboDyn develops breakthrough immunotherapies by identifying and targeting previously hidden disease markers through its proprietary RyboCypher™ technology platform. The company serves patients in need of next-generation treatments for diseases associated with cryptic biological targets.
- Who founded Rybodyn?
- Rybodyn was founded by Imad Ajjawi, Corey Dambacher, Kerry Wilson, Ashley Woodfin.
- Who are Rybodyn's investors?
- Rybodyn's investors include Swell Partners, SOSV.